Therapeutic utility of a novel tight junction modulating peptide for enhancing intranasal drug delivery

Journal of Pharmaceutical Sciences
Shu-Chih ChenHenry R Costantino

Abstract

Previously, a novel tight junction modulating (TJM) peptide was described affording a transient, reversible lowering of transepithelial electrical resistance (TER) in an in vitro model of nasal epithelial tissue. In the current report, this peptide has been further evaluated for utility as an excipient in transepithelial drug formulations. Chemical stability was optimal at neutral to acidic pH when stored at or below room temperature, conditions relevant to therapeutic formulations. The TJM peptide was tested in the in vitro tissue model for potential to enhance permeation of a low-molecular-weight (LMW) drug, namely the acetylcholinesterase inhibitor galantamine, as well as three peptides, salmon calcitonin, parathyroid hormone 1-34 (PTH(1-34)), and peptide YY 3-36 (PYY(3-36)). In all cases, the TJM peptide afforded a dramatic improvement in drug permeation across epithelial tissue. In addition, a formulation containing PYY(3-36) and TJM peptide was dosed intranasally in rabbits, resulting in a dramatic increase in bioavailability. The TJM peptide was as or more effective in enhancing PYY(3-36) permeation in vivo at a 1000-fold lower molar concentration compared to using LMW enhancers. Based on these in vitro and in vivo data,...Continue Reading

References

May 1, 1991·Pharmaceutical Research·F W MerkusN G Schipper
Aug 1, 1990·Pharmaceutical Research·M D DonovanG L Amidon
Mar 1, 1995·Diabetic Medicine : a Journal of the British Diabetic Association·P A CoatesD R Owens
Aug 1, 1994·Pharmaceutical Research·L IllumS S Davis
Sep 25, 1999·International Journal of Cancer. Journal International Du Cancer·L H BrinckerhoffC L Slingluff
Jun 6, 2000·Advanced Drug Delivery Reviews·A A Hussain
Jun 6, 2000·Advanced Drug Delivery Reviews·A E Pontiroli
Jun 6, 2000·Advanced Drug Delivery Reviews·V D RomeoC R Behl
Sep 23, 2000·International Journal of Pharmaceutics·R MitraA K Mitra
Jul 18, 2001·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·M A BaggerE Bechgaard
Feb 21, 2002·Journal of Controlled Release : Official Journal of the Controlled Release Society·K NakamuraK Takayama
Jul 13, 2002·Journal of Pharmaceutical Sciences·Dennis J PillionElias Meezan
Aug 15, 2002·Journal of Controlled Release : Official Journal of the Controlled Release Society·Kazuo OhtakeYasunori Morimoto
Jan 28, 2003·Drug Discovery Today·Priyanka AroraSanjay Garg
Mar 6, 2003·Journal of Controlled Release : Official Journal of the Controlled Release Society·Lisbeth Illum
Oct 9, 2003·Clinical Pharmacokinetics·Stanley S Davis, Lisbeth Illum
Dec 4, 2003·Drug Discovery Today·Kuresh A YoudimN Joan Abbott
Feb 6, 2004·Journal of Pharmaceutical Sciences·Fatima MustafaFakhrul Ahsan
Jul 14, 2004·Critical Reviews in Therapeutic Drug Carrier Systems·Yifan SongBozena Michniak
Nov 19, 2004·Neoplasia : an International Journal for Oncology Research·Robert GrützmannHans Detlev Saeger
Dec 14, 2004·Journal of Controlled Release : Official Journal of the Controlled Release Society·C PregoM J Alonso
Jun 30, 2005·Journal of Pharmaceutical Sciences·Alexis Kays LeonardHenry R Costantino
Nov 22, 2005·Expert Opinion on Drug Delivery·Paul H Johnson, Steven C Quay

❮ Previous
Next ❯

Citations

Sep 12, 2008·Biotechnology Letters·Snjezana Stolnik, Kevin Shakesheff
Sep 17, 2008·Pharmacogenetics and Genomics·Keith SextonKelly A BéruBé
Jul 28, 2012·Therapeutic Delivery·Catherine CampbellAnthony W Fox
Feb 25, 2014·Expert Opinion on Drug Discovery·Daniel SaaberStephan Reichl
Jun 20, 2008·Journal of Pharmaceutical Sciences·Shu-Chih Chen-QuaySteven C Quay
Oct 31, 2009·Journal of Pharmaceutical Sciences·Shyeilla V DhuriaWilliam H Frey
Mar 18, 2008·Drug Discovery Today·Paul H JohnsonHenry R Costantino
Jun 15, 2007·Archives of Medical Research·Marcelino CereijidoLiora Shoshani
May 4, 2007·International Journal of Pharmaceutics·Henry R CostantinoSteven C Quay
Dec 19, 2006·International Journal of Pharmaceutics·Alexis Kays LeonardHenry R Costantino
Apr 3, 2010·Drug Discovery Today·Xiaopin Duan, Shirui Mao
Sep 8, 2009·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Annette Wengst, Stephan Reichl
Sep 13, 2017·Expert Opinion on Drug Delivery·Gina LiIrina V Balyasnikova
Aug 21, 2020·CNS & Neurological Disorders Drug Targets·Manisha PandeyMuhammad Wahab Amjad

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Expert Opinion on Drug Delivery
Paul H Johnson, Steven C Quay
Journal of Controlled Release : Official Journal of the Controlled Release Society
Takahiro MatsuyamaHiroyuki Yoshino
Journal of Controlled Release : Official Journal of the Controlled Release Society
K NakamuraK Takayama
© 2022 Meta ULC. All rights reserved